



ASX/MEDIA RELEASE

20 September 2017

Mr Richard Hill to Retire as Chairman at Upcoming AGM

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) today advises that Mr Richard Hill has informed the Board of Directors that he intends to retire from his role as Independent Chairman and Non-Executive Director of the Company, and accordingly will not be standing for re-election as a Director at the upcoming Annual General Meeting to be held on Tuesday, 24 October 2017.

The Board has engaged a search firm and expects to announce Mr Hill's successor as soon as practicable following Mr Hill's last day as Chairman on 28 October 2017. Dr John Eady, Deputy Chairman of Sirtex Medical will assume the role of Interim Chairman until such time as a new Chairman is appointed, provided this is not finalised prior to the Annual General Meeting.

Dr John Eady commented "On behalf of the Board of Directors of Sirtex, I would like to thank Richard for all his tireless efforts over the last 13 years at Sirtex. Richard has overseen the development of a truly successful global medical device business, with a presence in over 40 countries and to date having supplied approximately 80,000 doses of our innovative SIR-Spheres® Y-90 resin microspheres to patients suffering from the debilitating effects of liver cancer."

Mr Richard Hill said "It has been an honour and privilege to serve as Chairman of Sirtex on behalf of our shareholders. Board renewal has been a focus of the Board over the last 24 months as the business continues to develop and new skills are required. I will therefore take great delight in introducing our two newest Non-Executive Directors, Ms Helen Kurincic and Mr Neville Mitchell to our shareholders at the upcoming AGM."

Mr Hill continued "I will be departing the Company knowing that the management team led by Mr Andrew McLean as CEO is capable of delivering on the inherent potential of the business moving forward. Importantly, the business is in an excellent financial position with \$118 million in cash and no debt at the end of FY17."

- ENDS -

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with approximately 80,000 doses supplied and administered over 1,090 medical centres in more than 40 countries.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About SIR-Spheres® Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union, Canada and Australia.

For further information please contact:

Investor Enquiries:

Dr John Eady
Deputy Chairman
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:
<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**
Visit us on LinkedIn: **Sirtex Medical Limited**

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd